Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| monoclonal antibodies | 5807 | None |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Serplulimab (HLX10) is a humanised monoclonal IgG4 antibody, which binds to the programmed cell death-1 (PD-1) receptor and blocks its interaction with ligands PD-L1 and PD-L2. The PD-1 receptor is a negative regulator of T-cell activity that has been shown to be involved in the control of T-cell immune responses. Engagement of PD-1 with the ligands PD-L1 and PD-L2, which are expressed in antigen presenting cells and may be expressed by tumours or other cells in the tumour microenvironment, results in inhibition of T-cell proliferation and cytokine secretion. Serplulimab potentiates T-cell responses, including anti-tumour responses, through blockade of PD-1 binding to PD-L1 and PD-L2 ligands.
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Feb. 3, 2025 | EMA | Accord Healthcare S.L.U. |
None
None
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Myelosuppression | 70.95 | 69.09 | 19 | 188 | 94321 | 110494771 |
None
| Source | Code | Description |
|---|---|---|
| ATC | L01FF12 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors |
| MeSH PA | D000074322 | Antineoplastic Agents, Immunological |
| MeSH PA | D000970 | Antineoplastic Agents |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Small cell lung cancer | indication | 254632001 | DOID:5409 |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Programmed cell death protein 1 | Membrane receptor | BLOCKER | Kd | 8.62 | SCIENTIFIC LITERATURE | DRUG LABEL |
| ID | Source |
|---|---|
| 2231029-82-4 | SECONDARY_CAS_RN |
| CHEMBL4594550 | ChEMBL_ID |
| C000732065 | MESH_SUPPLEMENTAL_RECORD_UI |
| C5418260 | UMLSCUI |
| CHEBI:758023 | CHEBI |
| 11176 | INN_ID |
| 13796 | IUPHAR_LIGAND_ID |
| S3GQZ2K36V | UNII |
| D12751 | KEGG_DRUG |
None